CSIMarket
 
Bristol myers Squibb Company  (NYSE: BMY)
Other Ticker:  
 
 
Price: $46.8600 $0.02 0.043%
Day's High: $47.395 Week Perf: -5.81 %
Day's Low: $ 46.72 30 Day Perf: -2.11 %
Volume (M): 47,287 52 Wk High: $ 63.33
Volume (M$): $ 2,215,878 52 Wk Avg: $52.41
Open: $46.92 52 Wk Low: $39.35



 Market Capitalization (Millions $) 95,907
 Shares Outstanding (Millions) 2,047
 Employees 34,100
 Revenues (TTM) (Millions $) 47,636
 Net Income (TTM) (Millions $) 5,437
 Cash Flow (TTM) (Millions $) 1,541
 Capital Exp. (TTM) (Millions $) 1,224

Bristol Myers Squibb Company
Bristol-Myers Squibb Company Overview

Incorporation and History:
Bristol-Myers Squibb Company (BMS) was incorporated in August 1933 in Delaware as Bristol-Myers Company. Its origins trace back to 1887 with a New York-based business. In 1989, the company underwent a significant transformation, merging with Squibb Corporation and adopting the name Bristol-Myers Squibb Company.

Business Segments:
Bristol-Myers Squibb is a global biopharmaceutical company focusing on the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and healthcare products. The company is organized into four reportable segments:

1. Pharmaceuticals: This segment encompasses the global pharmaceutical business, including exclusive consumer medicines outside Japan. BMSs portfolio includes a range of therapeutic areas such as cardiovascular disease, immunology, and virology.

2. Oncology Therapeutics Network (OTN): The OTN segment provides oncology products, supportive care products, and related supplies to U.S. office-based oncologists, focusing on providing integrated solutions for cancer treatment.

3. Nutritionals: This segment includes Mead Johnson Nutritionals, a leading brand in infant formula and nutritional products for infants and children, emphasizing nutritional science and product innovation.

4. Other Healthcare: This diverse segment includes businesses such as ConvaTec (which focuses on advanced wound care, continence, and urology), Medical Imaging, and consumer medicines marketed in North America and Japan.

Marketing and Sales Strategies:
Bristol-Myers Squibb employs a robust marketing strategy that includes promoting its products through medical journals and direct communication with healthcare providers, including doctors, nurse practitioners, and hospitals. In addition, the company engages in direct-to-consumer advertising across various media platforms in the United States.

The company operates several pharmaceutical sales organizations tailored to specific therapeutic areas and physician specialties. These targeted sales strategies are particularly effective when launching new products, enabling focused marketing efforts that tap into specialized care environments.

Distribution Channels:
Bristol-Myers Squibbs pharmaceutical products are primarily sold to wholesalers, though direct sales are made to various healthcare entities, including retailers, hospitals, clinics, government agencies, and pharmacies. Major wholesalers in the U.S. market include McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation.

Competitive Landscape:
Bristol-Myers Squibb operates in a highly competitive landscape characterized by broad market participation from both large research-based drug companies and smaller firms focused on niche therapeutic areas. The main competitive factors influencing the pharmaceutical segment include:

- Product Efficacy and Safety: Ensuring that drugs provide favorable outcomes and are well-tolerated by patients.
- Cost-Effectiveness: Demonstrating value through pricing and economic benefits of therapy.
- Marketing and Labeling: Effectiveness in communication to both healthcare providers and patients, including drug labeling and educational efforts.
- Innovation in Research and Development: Ongoing investment in research to bring new therapeutic options to market, particularly in response to emerging health needs and diseases.

The competitiveness is further intensified by the quick adoption and potential market penetration of generic drugs, which can significantly impact the sales of branded pharmaceuticals. Consequently, BMS remains diligent in monitoring clinical studies and market dynamics that could affect its product performance.

Recent Developments and Focus Areas:
Bristol-Myers Squibb continuously emphasizes research and innovation, focusing on the development of breakthrough therapies in oncology, immunology, and cardiovascular disease. The company has made strides in precision medicine and targeted therapies, enhancing treatment options for patients with various conditions. Additionally, Bristol-Myers Squibb is increasingly investing in digital health solutions and collaborative partnerships as part of its strategic approach to healthcare delivery and education.

Overall, Bristol-Myers Squibb remains committed to advancing medical science and improving patient outcomes through its comprehensive portfolio and strategic initiatives in drug discovery and development.


   Company Address: Route 206 & Province Line Road Princeton 8543 NJ
   Company Phone Number: 252-4621   Stock Exchange / Ticker: NYSE BMY


Customers Net Income grew by BMY's Customers Net Profit Margin grew to


2.68 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.02%    
ABT   -1.94%    
JNJ   -4.65%    
LLY   -6.91%    
MRK   -3.24%    
PFE   -2.32%    
• View Complete Report
   



Partnership

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-gener...

Published Mon, Jun 2 2025 11:14 AM UTC

BioNTech and Bristol Myers Squibb Forge Strategic Alliance for Bispecific Antibody Development Amid Competitive Market Pressures MAINZ, Germany, and PRINCETON, USA June 2, 2025 In a significant move that underscores the dynamic landscape of oncology therapeutics, BioNTech (Nasdaq: BNTX) and Bristol Myers Squibb (NYSE: BMY) have announced a global strategic partnership ...

Business Update

Harnessing AI to Shape the Future of Therapeutics A Landmark Collaboration between AI Proteins and Bristol Myers Squibb

Published Tue, Dec 3 2024 2:47 PM UTC

In a groundbreaking move that promises to reshape the landscape of drug development, AI Proteins, Inc. a pioneer in computational de novo protein design has announced a strategic Research Collaboration and Option Agreement with the pharmaceutical giant Bristol Myers Squibb (BMS). This partnership aims to harness the power of AI-driven miniprotein therapeutics, potentially yi...

Bristol Myers Squibb Company

Bristol Myers Squibb Thrives in Q2 2024: Resilient Performance Amid Market Challenges

Bristol Myers Squibb Company, a major player in the pharmaceutical industry, has faced challenges in its share performance this year. Year to date, the company's shares have trailed the overall market, which has seen a 15.45% increase. While this decline in share value can be concerning, it is important to note that Bristol Myers Squibb continues to maintain a strong market presence.
One recent event that may have impacted the company's stock performance is its participation in the UBS Virtual Targeted Protein Degradation Day. This event allows Bristol Myers Squibb to showcase its expertise in this innovative area of research. While this participation demonstrates the company's commitment to advancing research and development, it does not guarantee an immediate positive impact on the stock value.

Stocks on the Move

Bristol Myers Squibb Faces Challenges but Maintains Strong Market Presence

Published Tue, Jul 9 2024 4:27 PM UTC

Bristol Myers Squibb Company Shares Face Challenges but Maintain Strong Market PresenceBristol Myers Squibb Company shares have experienced a decline in performance this week, trailing behind the overall market. This drop in share value can be attributed to several recent events and factors that have impacted the company s stock. However, despite these challenges, Bristol My...

Stocks on the Move

s with its recent developments, collaborations, and financial performance. The termination of the ADC development deal with Eisai reflects the companys prioritization strategy,...

Published Wed, Jul 3 2024 11:19 AM UTC

Exploring Recent Developments and Financial Performance of Bristol Myers Squibb in the Pharmaceutical IndustryIn the fast-paced and ever-evolving pharmaceutical industry, companies constantly strive to develop innovative drugs and treatments to address critical medical needs. Bristol Myers Squibb, a renowned pharmaceutical company, has been at the forefront of such advanceme...







Bristol Myers Squibb's Segments
Collaborative Arrangement    33.24 % of total Revenue
Net product sales    97.19 % of total Revenue
Net product sales Collaborative Arrangement    32.45 % of total Revenue
Alliance revenues Collaborative Arrangement    0.79 % of total Revenue
Other revenues    2.03 % of total Revenue
United States    70.29 % of total Revenue
Gross product sales    177.43 % of total Revenue
International    27.77 % of total Revenue
Other    1.95 % of total Revenue
Growth Portfolio    49.67 % of total Revenue
Opdivo    20.22 % of total Revenue
Opdivo Qvantig    0.08 % of total Revenue
Orencia    6.87 % of total Revenue
Yervoy    5.57 % of total Revenue
Reblozyl    4.27 % of total Revenue
Opdualag    2.25 % of total Revenue
Breyanzi    2.35 % of total Revenue
Camzyos    1.42 % of total Revenue
Zeposia    0.96 % of total Revenue
Abecma    0.92 % of total Revenue
Sotyktu    0.49 % of total Revenue
Krazati    0.43 % of total Revenue
Cobenfy    0.24 % of total Revenue
Other Growth products    3.6 % of total Revenue
Legacy Portfolio    50.33 % of total Revenue
Eliquis    31.83 % of total Revenue
Revlimid    8.36 % of total Revenue
Pomalyst Imnovid    5.87 % of total Revenue
Sprycel    1.56 % of total Revenue
Abraxane    0.94 % of total Revenue
Other Legacy products    1.78 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com